Cyberounds Logo
January 19, 2020 | LOGIN | REGISTER | HELP | 
email a friend print Bookmark and Share
Idiopathic Pulmonary Fibrosis
CME credit is no longer available for this conference.
Harold R. Collard, M.D., and Talmadge E. King, Jr., M.D.

Dr. Collard is Assistant Clinical Professor and Dr. King is Professor and Chair, Department of Medicine, UCSF School of Medicine, San Francisco, California.

Within the past 12 months, Dr. Collard has been a consultant to InterMune and Dr. King has been a consultant to Alexz, Actelion, AstraZeneca, Biogen, Boehringer Ingelheim, Centocor, CoTherix, FibroGen, GlaxoSmithKline, Genentech, Genzyme, Human Genome Sciences, InterMune, Merck, Millennium Pharmaceutical, Nekta, Otsuka America and Serono International.

Release Date: 06/07/2006
Termination Date: 06/07/2009

Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Learning Objectives
Upon completion of this Cyberounds®, you should be able to:
  • Discuss the current approach to the diagnosis of idiopathic pulmonary fibrosis
  • Describe the natural history of idiopathic pulmonary fibrosis and how to approach prognosis
  • Describe the data behind potential therapies for idiopathic pulmonary fibrosis and establish an approach to management that is evidence-based.

This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
Please click below to accept the terms of this CME activity